Bank of America’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.8M | Sell |
330,720
-15,927
| -5% | -$512K | ﹤0.01% | 2893 |
|
|
2025
Q4 | $12.2M | Sell |
346,647
-231,621
| -40% | -$8.21M | ﹤0.01% | 2699 |
|
|
2025
Q3 | $15.2M | Buy |
578,268
+53,496
| +10% | +$1.6M | ﹤0.01% | 2872 |
|
|
2025
Q2 | $13.9M | Buy |
524,772
+163,062
| +45% | +$4.29M | ﹤0.01% | 2912 |
|
|
2025
Q1 | $8.74M | Buy |
361,710
+159
| +0% | +$5.03K | ﹤0.01% | 3275 |
|
|
2024
Q4 | $14.5M | Sell |
361,551
-61,282
| -14% | -$3.49M | ﹤0.01% | 2587 |
|
|
2024
Q3 | $26.8M | Sell |
422,833
-7,949
| -2% | -$466K | ﹤0.01% | 2121 |
|
|
2024
Q2 | $22.8M | Buy |
430,782
+18,367
| +4% | +$1.2M | ﹤0.01% | 2113 |
|
|
2024
Q1 | $33.8M | Sell |
412,415
-358,208
| -46% | -$15.9M | ﹤0.01% | 1786 |
|
|
2023
Q4 | $14.3M | Buy |
770,623
+78,349
| +11% | +$1.02M | ﹤0.01% | 2485 |
|
|
2023
Q3 | $7.66M | Buy |
692,274
+287,508
| +71% | +$4.11M | ﹤0.01% | 2996 |
|
|
2023
Q2 | $6.56M | Sell |
404,766
-385,079
| -49% | -$8.07M | ﹤0.01% | 3132 |
|
|
2023
Q1 | $13.2M | Buy |
789,845
+692,945
| +715% | +$7.16M | ﹤0.01% | 2541 |
|
|
2022
Q4 | $911K | Sell |
96,900
-20,880
| -18% | -$93.2K | ﹤0.01% | 4926 |
|
|
2022
Q3 | $320K | Sell |
117,780
-3,081
| -3% | -$10.1K | ﹤0.01% | 5703 |
|
|
2022
Q2 | $349K | Buy |
120,861
+70,298
| +139% | +$174K | ﹤0.01% | 5689 |
|
|
2022
Q1 | $152K | Sell |
50,563
-4,058
| -7% | -$14.6K | ﹤0.01% | 6628 |
|
|
2021
Q4 | $251K | Sell |
54,621
-237,961
| -81% | -$1.33M | ﹤0.01% | 6362 |
|
|
2021
Q3 | $1.84M | Buy |
292,582
+14,839
| +5% | +$91.7K | ﹤0.01% | 4519 |
|
|
2021
Q2 | $1.66M | Sell |
277,743
-111,343
| -29% | -$661K | ﹤0.01% | 4479 |
|
|
2021
Q1 | $2.46M | Buy |
389,086
+138,468
| +55% | +$974K | ﹤0.01% | 4077 |
|
|
2020
Q4 | $1.41M | Sell |
250,618
-49,300
| -16% | -$299K | ﹤0.01% | 4233 |
|
|
2020
Q3 | $1.75M | Buy |
299,918
+2,905
| +1% | +$20K | ﹤0.01% | 3784 |
|
|
2020
Q2 | $2.14M | Buy |
297,013
+16,054
| +6% | +$107K | ﹤0.01% | 3573 |
|
|
2020
Q1 | $1.31M | Buy |
280,959
+13,080
| +5% | +$80.4K | ﹤0.01% | 3824 |
|
|
2019
Q4 | $2.15M | Sell |
267,879
-46,271
| -15% | -$337K | ﹤0.01% | 3969 |
|
|
2019
Q3 | $2.16M | Sell |
314,150
-234,445
| -43% | -$1.74M | ﹤0.01% | 3980 |
|
|
2019
Q2 | $4.55M | Sell |
548,595
-351,419
| -39% | -$3M | ﹤0.01% | 3326 |
|
|
2019
Q1 | $8.95M | Buy |
900,014
+647,405
| +256% | +$5.42M | ﹤0.01% | 2595 |
|
|
2018
Q4 | $1.93M | Buy |
252,609
+242,296
| +2,349% | +$2.9M | ﹤0.01% | 3867 |
|
|
2018
Q3 | $180K | Sell |
10,313
-173
| -2% | -$2.06K | ﹤0.01% | 5542 |
|
|
2018
Q2 | $100K | Sell |
10,486
-5,790
| -36% | -$38.5K | ﹤0.01% | 5789 |
|
|
2018
Q1 | $71K | Buy |
+16,276
| New | +$90K | ﹤0.01% | 5900 |
|
Other funds holding VKTX
VCM
VPM
Bank of America's VKTX Position: Q1 2026 in Review
Bank of America reduced its Viking Therapeutics (VKTX) stake by 4.6% in Q1 2026, selling an estimated $512K and leaving 330,720 shares worth $10.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2893.
Bank of America first reported a position in VKTX in Q1 2018 and has held it in 33 quarters since. The position peaked at $33.8M in Q1 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.
- Bank of America held 330,720 shares of Viking Therapeutics worth $10.8M as of Q1 2026.
- Bank of America sold 15,927 Viking Therapeutics shares in Q1 2026, an estimated $512K.
- Viking Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2893 holding.
- Bank of America first reported a position in Viking Therapeutics in Q1 2018 and has held it in 33 quarters since.
- Bank of America's Viking Therapeutics position peaked at $33.8M in Q1 2024.
- 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.